Tesamorelin Peptide 10mg

Compound Class and Structure Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone releasing hormone (GHRH), supplied as a lyophilized white powder in sealed vials for laboratory research use only. The sequence corresponds to full-length GHRH(1–44), with a trans-3-hexenoyl group attached at the N-terminal tyrosine. This acyl modification sterically shields the N-terminus from dipeptidyl peptidase-4 (DPP-4) cleavage — the principal enzymatic route that fragments native GHRH in plasma and serum-containing culture media — so the intact molecule persists across longer assay windows than the unmodified parent sequence. Receptor Pharmacology and Signalling The molecular target is the GHRH receptor (GHRHR), a class B1 secretin-family G protein-coupled receptor expressed densely on anterior pituitary somatotrophs. Agonist occupancy drives Gs coupling, adenylyl cyclase activation and cyclic AMP accumulation, with downstream protein kinase A activity, CREB phosphorylation and GH1 transcriptional readouts, alongside voltage-gated calcium entry that supports secretory granule release. Released growth hormone then engages hepatic and peripheral growth hormone receptors, activating JAK2/STAT5 signalling and IGF-1 and IGFBP-3 expression. Because somatostatinergic tone and IGF-1 feedback shape the same circuit, the analogue is widely used as a probe of feedback architecture rather than of a single receptor in isolation. Research Areas, Models and Endpoints In vitro work u